Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically
inferior to the control drug after 32 weeks of administration to patients with suppressed
tear production due to moderate or severe dry eye syndrome.